Signaturefd LLC Acquires 2,849 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Signaturefd LLC increased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 1,656.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,021 shares of the company’s stock after buying an additional 2,849 shares during the period. Signaturefd LLC’s holdings in Travere Therapeutics were worth $27,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Travere Therapeutics by 968.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock worth $51,000 after buying an additional 5,121 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Travere Therapeutics by 353.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock worth $78,000 after buying an additional 6,773 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Travere Therapeutics by 32.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock worth $148,000 after buying an additional 4,007 shares during the period. Teacher Retirement System of Texas boosted its holdings in Travere Therapeutics by 9.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 18,804 shares of the company’s stock worth $168,000 after buying an additional 1,641 shares during the period. Finally, Arizona State Retirement System boosted its holdings in Travere Therapeutics by 9.7% in the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock worth $189,000 after buying an additional 1,851 shares during the period.

Travere Therapeutics Price Performance

Shares of TVTX stock opened at $6.26 on Friday. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. The company has a market capitalization of $476.45 million, a P/E ratio of -3.83 and a beta of 0.69. The company’s 50-day simple moving average is $7.10 and its two-hundred day simple moving average is $7.61. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $19.54.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.11. The business had revenue of $45.06 million for the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. As a group, equities analysts anticipate that Travere Therapeutics, Inc. will post -3.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TVTX shares. Wells Fargo & Company upped their target price on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Wedbush reissued an “outperform” rating and set a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Piper Sandler increased their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, January 18th. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Finally, HC Wainwright increased their price objective on shares of Travere Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.